Research programme: uridine therapeutics - RepligenAlternative Names: Anxiety disorder therapeutics - Repligen; Uridine analogues - Repligen; Uridine therapeutics - Repligen
Latest Information Update: 11 Oct 2007
At a glance
- Originator Repligen
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anxiety disorders; Bipolar disorders
Most Recent Events
- 28 Oct 2004 Preclinical trials in Anxiety disorders in USA (unspecified route)